Integra LifeSciences Holdings Beats Analyst Estimates on EPS

Seth Jayson, The Motley Fool
Updated

Integra LifeSciences Holdings (NAS: IART) reported earnings on Feb. 21. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Dec. 31 (Q4), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share expanded. GAAP earnings per share expanded significantly.


Gross margins were steady, operating margins contracted, net margins grew.

Revenue details
 Integra LifeSciences Holdings booked revenue of $214.4 million. The 14 analysts polled by S&P Capital IQ expected revenue of $215.9 million on the same basis. GAAP reported sales were 5.4% higher than the prior-year quarter's $203.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.78. The 16 earnings estimates compiled by S&P Capital IQ forecast $0.76 per share. Non-GAAP EPS of $0.78 for Q4 were 8.3% higher than the prior-year quarter's $0.72 per share. GAAP EPS of $0.46 for Q4 were 188% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 61.8%, much about the same as the prior-year quarter. Operating margin was 8.7%, 410 basis points worse than the prior-year quarter. Net margin was 6.0%, 380 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $206.0 million. On the bottom line, the average EPS estimate is $0.70.

Next year's average estimate for revenue is $871.3 million. The average EPS estimate is $3.19.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 155 members out of 164 rating the stock outperform, and nine members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.08.

Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Integra LifeSciences Holdings Beats Analyst Estimates on EPS originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement